Evidence map›Paper›PMID 30333744›Full record

ArticleFrontiers in aging neuroscience2018

Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers.

Shraddha Sapkota, Tao Huan, Tran Tran, Jiamin Zheng, Richard Camicioli, Liang Li, Roger A Dixon

Open access · goldAbstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. An Update of Salivary Biomarkers for the Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Biomarkers in Alzheimer's disease.Advances in laboratory medicine · 2021
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shraddha SapkotaNeuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
Tao HuanDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Tran TranDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Jiamin ZhengDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Richard CamicioliNeuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
Liang LiDepartment of Chemistry, University of Alberta, Edmonton, AB, Canada.
Roger A DixonNeuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
University of Alberta · CAWomen and Children’s Health Research Institute · CA

Funding

LONGITUDINAL STUDY OF COGNITIVE AGINGR01AG008235 · NIA · UNIVERSITY OF VICTORIA · PI DIXON, ROGER A · 1989 to 2017
$2.3M
NIA NIH HHS R01 AG008235
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer’s diseasebiomarkerscognitioncognitively normalgeneticsmild cognitive impairmentsalivary metabolomicsvictoria longitudinal study

Identifiers

PMID30333744
PMCPMC6175993
OpenAlexW2894884164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.